A Novel Dye Exclusion Method for Testing in Vitro Chemosensitivity of Human Tumors

Cancer Research

Volumn 43, Issue 2, 1983, Pages 749-757

  Weisenthal, Larry M ^a,b   Marsden, Joye A ^a   Dill, Patricia L ^a  

^a VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; CHLORMETHINE; CISPLATIN; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; LOMUSTINE; MELPHALAN; METHOTREXATE; MITOMYCIN; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

BLOOD AND HEMOPOIETIC SYSTEM; CANCER CELL; CANCER CHEMOTHERAPY; CELL CULTURE; CELL STAINING; CYTOLOGY; DRUG SCREENING; DRUG SENSITIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL; THERAPY;

ANTINEOPLASTIC AGENTS; CELL LINE; CELL SURVIVAL; DOXORUBICIN; DRUG EVALUATION, PRECLINICAL; EOSINE YELLOWISH-(YS); ETOPOSIDE; FLUOROURACIL; HEMATOXYLIN; HUMAN; LEUKEMIA, MYELOCYTIC, ACUTE; MECHLORETHAMINE; MELPHALAN; NEOPLASMS; STAINING AND LABELING; SUPPORT, U.S. GOV'T, NON-P.H.S.;

EID: 0020684733     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Barranco, S. C. Review of the survival and cell kinetics effects of Adriamycin (NSC-123127) on mammalian cells. Cancer Chemother. Rep. Part 3, 6. 147–152, 1975.
2. Bender, R. A., Geiger, W. A., Drake, J. C., and Ziegler, J. L. In vitro correlates of clinical response to methotrexate in acute leukemia and Burkitt's lymphoma. Br. J. Cancer, 34: 484–492, 1976.
3. Bhuyan, B. K., Loughman, B. E., Fraser, T. J., and Day, K. J. Comparison of different methods of determining cell viability after exposure to cytotoxic compounds. Exp. Cell Res., 97: 275–280, 1976.
4. Bickis, I. J., Henderson, I. W., and Quastel, J. H. Biochemical studies of human tumors. Cancer (Phila.), 19: 103–113, 1966.
5. Black, M. M., and Speer, F. D. Further observations on the effects of cancer chemotherapeutic agents on the in vitro dehydrogenase activity of cancer tissue. J. Natl. Cancer Inst., 14: 1147–1158, 1954.
6. Collins, S. J., Ruscetti, F. W., Gallagher, R. E., and Gallo, R. C. Terminal differentiation of human promyelocytic leukemia cells induced by dimethyl sulfoxide and other polar compounds. Proc. Natl. Acad. Sci. U. S. A., 75: 2458–2462, 1978.
7. Dendy, P. P., Bozman, G., and Wheeler, T. K. In vitro screening test for human malignant tumors before chemotherapy. Lancet, 2: 68–72, 1970.
8. Dickson, J. A., and Suzanger, M. In vitro sensitivity testing of human tumor slices to chemotherapeutic agents-its place in cancer therapy. In: P. P. Dendy (ed.), Human Tumors in Short-Term Culture, pp. 107–138. London: Academic Press, Inc., 1976.
9. DiPaolo, J. A. Analysis of an individual chemotherapy assay system. Natl. Cancer Inst. Monogr. 34: 240–245, 1971.
10. Durkin, W. J., Ghanta, V. K., Balch, C. M., Davis, D. W., and Hiramoto, R. N. A methodological approach to the prediction of anticancer drug effect in humans. Cancer Res., 39: 402–407, 1978.
11. Grinnell, F., Milan, M., and Srere, P. A. Studies on cell adhesion. II. Adhesion of cells to surfaces of diverse chemical composition and inhibition of adhesion by sulfhydryl binding reagents. Arch. Biochem. Biophys., 153: 193–198, 1972.
12. Hansen, H. H., Bender, R. A., and Shelton, B. J. The cytocentrifuge and cerebrospinal fluid cytology. Acta Cytol., 18: 259–262, 1974.
13. Holmes, H. L., and Little, J. M. Tissue culture microtest for predicting response of human cancer to chemotherapy. Lancet, 2: 985–987, 1974.
14. Kaltenbach, J. P., Kaltenbach, M. H., and Lyons, W. B. Nigrosin as a dye for differentiating live and dead ascites cells. Exp. Cell Res., 15: 112–117, 1958.
15. Knock, F. E., Galt, R. M., Oester, Y. T., and Sylvester, R. In vitro estimate of sensitivity of individual human tumors to antitumor agents. Oncology (Basel), 30: 1–22, 1974.
16. Komp, D. M., and Cox, B. J. Cytocentrifugation in the management of central nervous system leukemia. J. Pediatr., 87: 992–994, 1972.
17. Limburg, H. Individualized chemotherapy of ovarian cancer by means of the tissue culture method. In: P. P. Dendy (ed.), Human tumars in Short-Term Culture, pp. 293–300. London: Academic Press, Inc., 1976.
18. Limburg, H., and Heckman, U. Chemotherapy in the treatment of advanced pelvic malignant disease with special reference to ovarian cancer. J. Obstet. Gynaecol. Br. Emp., 75: 1246–1255, 1968.
19. Livingston, R. B. Depression of thymidine labeling index in vitro predicts effects of chemotherapy in patients. Proc. Am. Soc. Cancer Res., 20: 316, 1979.
20. Mattern, J., Kaufmann, M., Wayss, K., and Volm, M. Studies on the drug sensitivity of short-term cultured tumor cell suspensions. In: P. P. Dendy (ed.), Human Tumors in Short-Term Culture, pp. 301–310. London: Academic Press, Inc., 1976.
21. Park, C. H., Amare, M., Savin, M. A., Goodwin, J. W., Newcomb, M. M., and Hoogstaten, B. Prediction of chemotherapy response in human leukemia using an in vitro chemotherapy sensitivity test on the leukemia colony-forming cells. Blood, 55: 595–601, 1980.
22. Pavelic, Z. P., Slocum, H., Rustum, Y. M., Creaver, P. J., Karakousis, C., Takita, H., and Mittelman, A. Growth of human solid tumor cell colonies in soft agar. Proc. Am. Assoc. Cancer Res., 21: 329, 1980.
23. Phillips, H. J., and Terryberry, J. E. Counting actively metabolizing tissue cultured cells. Exp. Cell Res., 13: 341–347, 1957.
24. Raich, P. C. Prediction of therapeutic response in acute leukemia. Lancet, 1: 74–76, 1978.
25. Roper, P. R., and Drewinko, B. Comparison of in vitro methods to determine drug-induced cell lethality. Cancer Res., 36: 2182–2188, 1976.
26. Salmon, S. E., Alberts, D. S., Durie, B. G. M., Meyskens, F. L., Soehnlen, B., Chen, H-S. G., and Moon, T. Clinical correlations of drug sensitivity in the human tumor stem cell assay. Recent Results Cancer Res., 74: 300–305, 1980.
27. Salmon, S. E., Hamburger, A. W., Soehnlen, B. J., Durie, B. G. M., Alberts, D. S., and Moon, T. C. Quantitation of differential sensitivities of human tumor stem cells to anticancer drugs. N. Engl. J. Med., 298: 1321–1327, 1978.
28. Shrek, R. A method for counting the viable cells in normal and in malignant cell suspensions. Am. J. Cancer, 28: 389–392, 1936.
29. Sky-Peck, H. H. Effects of chemotherapy on the incorporation of [3H]thymidine into DNA of human neoplastic tissue. Natl. Cancer Inst. Monogr., 34: 197–203, 1971.
30. Warenius, H. M. Detection of acquired resistance to cytotoxic drugs in vivo by short-term in vitro cultures of human tumors. In: P. P. Dendy (ed.), Human Tumors in Short-Term Culture, pp. 311–320. London: Academic Press, Inc., 1976.
31. Weisenthal, L. M. In vitro assays in preclinical antineoplastic drug screening. Semin. Oncol., 8: 362–376, 1981.
32. Wheeler, T. K., Dendy, P. P., and Dawson, A. Assessment for an in vitro screening test of cytotoxic agents in the treatment of advanced malignant disease. Oncology (Basel), 30: 362–376, 1974.
33. Wolberg, W. H. Biochemical approaches to prediction of response in solid tumors. Natl. Cancer Inst. Monogr., 34: 189–195, 1971.
34. Yataganas, X., Strife, A., Perez, A., and Clarkson, B. D. Microfluorimetric evaluation of cell kill kinetics with 1-ß-D-arabinofuranosylcytosine. Cancer Res., 34: 2795–2806, 1974.
35. Yuhas, J. M., Toya, R. E., and Pazmina, N. H. Neuraminidase and cell viability: failure to detect cytotoxic effects with dye-exclusion techniques. J. Natl. Cancer Inst., 53. 465–468, 1974.